Mechanistically, TSLNC8 activates the MAPK signaling pathway by regulating the accumulation of PP1α in the cytoplasm and promotes the sensitivity of tumor cells to PLX4720, which enables melanoma patients to benefit from the combined treatment of PLX4720 and TSLNC8 (134). The gene discussed is LINC00589; the disease is neoplasm.